Colorectal cancer molecular profiling: Opportunities for early detection

Abstract

Colorectal cancer (CRC) is one of the most common and deadliest cancers worldwide, and incidence rates are rising. However, early detection and intervention can improve the survival rates and quality of life of affected patients. Current screening tests used to streamline patients into colonoscopy either lack test adherence or sensitivity for detecting premalignant and early-stage CRC, reducing the advantages of screening measures. Cost-effective and minimally invasive diagnostic tests which can detect immune system and metabolic changes are key to lower the incidence of CRC advanced stages. We herein discuss the statistics, risk factors and unique genetic characteristics of CRC, focussing on the importance of understanding non tumour-derived information in premalignant states for developing comprehensive techniques to achieve earlier diagnosis of CRC. Moreover, the advantages and limitations of current UK and USA screening programmes and emerging detection tools are discussed, along with prospective diagnostics such as genomics, proteomics and spectroscopy.

Keywords

cancer / colorectal / CRC / detection / diagnostics / early-onset / early-stage / liquid biopsy

References

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74: 12-49.

[2] Willauer AN, Liu Y, Pereira AAL, et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019; 125: 2002-2010.

[3] WHO. IARC. Cancer Tomorrow n.d. https://gco.iarc.who.int/tomorrow/(accessed August 15, 2025).

[4] Ullah F, Pillai AB, Omar N, Dima D, Harichand S. Early-onset colorectal cancer: current insights. Cancers (Basel). 2023; 15: 3202.

[5] Mauri G, Sartore-Bianchi A, Russo A, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019; 13: 109-131.

[6] Bailey CE, Hu C-Y, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015; 150: 17-22.

[7] Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 2025; 75: 10-45.

[8] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clinicians. 2022; 72: 7-33.

[9] Gimeno-García AZ, Quintero E. Role of colonoscopy in colorectal cancer screening: available evidence. Best Practice & Research Clinical Gastroenterology. 2023; 66: 101838.

[10] Monahan KJ, Bradshaw N, Dolwani S, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020; 69: 411-444.

[11] WHO. IARC. Cancer Today n.d. https://gco.iarc.who.int/today/ (accessed February 17, 2025)

[12] NIH. Screening Tests to Detect Colorectal Cancer and Polyps—NCI 2024. https://www.cancer.gov/types/colorectal/screening-fact-sheet (accessed February 17, 2025)

[13] Sadien I, Davies R, Wheeler J. The genomics of sporadic and hereditary colorectal cancer. Ann R Coll Surg Engl. 2024; 106: 313-320.

[14] Abbott J, Näthke IS. The adenomatous polyposis coli protein 30 years on. Seminars in Cell & Developmental Biology. 2023: 150-151: 28–34.

[15] Parker TW, Neufeld KL. APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes. Sci Rep. 2020; 10: 2957.

[16] Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004; 23: 11-27.

[17] Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Ann Oncol. 2019; 30: 520-527.

[18] Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350-1356.

[19] Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer—a call to action. Nat Rev Clin Oncol. 2021; 18: 230-243.

[20] Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023; 9: 1-21.

[21] Anderson JC, Samadder JN. To screen or not to screen adults 45-49 years of age: that is the question. Am J Gastroenterol. 2018; 113: 1750-1753.

[22] Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2018; 68: 250-281.

[23] Gupta S, May FP, Kupfer SS, Murphy CC. Birth cohort colorectal cancer (CRC): implications for research and practice. Clin Gastroenterol Hepatol. 2024; 22: 455-469. e7.

[24] Li H, Boakye D, Chen X, et al. Associations of body mass index at different ages with early-onset colorectal cancer. Gastroenterology. 2022; 162: 1088-1097. e3.

[25] Jin EH, Han K, Shin CM, et al. Sex and Tumor-site differences in the association of alcohol intake with the risk of early-onset colorectal cancer. J Clin Oncol. 2023; 41: 3816-3825.

[26] Hur J, Otegbeye E, Joh H-K, et al. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. Gut. 2021; 70: 2330-2336.

[27] Saraiva MR, Rosa I, Claro I. Early-onset colorectal cancer: a review of current knowledge. World Journal of Gastroenterology. 2023; 29: 1289-1303.

[28] Mauri G, Patelli G, Sartore-Bianchi A, et al. Early-onset cancers: biological bases and clinical implications. Cell Reports Medicine. 2024; 5: 101737.

[29] Monahan KJ, Davies MM, Abulafi M, et al. Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG). Gut. 2022; 71: 1939-1962.

[30] Imperiale TF, Porter K, Zella J, et al. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med. 2024; 390: 984-993.

[31] Press Release. Guardant Health's ShieldTM Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening 2024. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Healths-Shield-Blood-Test-Approved-by-FDA-as-a-Primary-Screening-Option-Clearing-Path-for-Medicare-Reimbursement-and-a-New-Era-of-Colorectal-Cancer-Screening/default.aspx (accessed February 17, 2025)

[32] Nguyen HT, Duong H-Q. The molecular characteristics of colorectal cancer: implications for diagnosis and therapy. Oncol Lett. 2018; 16: 9-18.

[33] Sala A, Cameron JM, Brennan PM, et al. Global serum profiling: an opportunity for earlier cancer detection. Journal of Experimental & Clinical Cancer Research. 2023; 42: 207.

[34] Hanahan D. Hallmarks of Cancer: new Dimensions. Cancer Discovery. 2022; 12: 31-46.

[35] Cruz MD, Ledbetter S, Chowdhury S, et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget. 2017; 8: 20543.

[36] Hardbower DM, Coburn LA, Asim M, et al. EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Oncogene. 2017; 36: 3807-3819.

[37] Bui TM, Butin-Israeli V, Wiesolek HL, et al. Neutrophils alter DNA repair landscape to impact survival and shape distinct therapeutic phenotypes of colorectal cancer. Gastroenterology. 2021; 161: 225-238. e15

[38] Noble A, Durant L, Dilke SM, et al. Altered mucosal immune-microbiota interactions in familial adenomatous polyposis. Clinical and Translational Gastroenterology. 2022; 13: e00428.

[39] Piciocchi A, Germinario EAP, Garcia Etxebarria K, et al. Association of Polygenic Risk Score and Bacterial Toxins at Screening Colonoscopy with Colorectal Cancer Progression: a Multicenter Case-Control Study. Toxins. 2021; 13: 569.

[40] Bai X, Wei H, Liu W, et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites. Gut. 2022; 71: 2439-2450.

[41] Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World J Gastroenterol. 2017; 23: 3632-3642.

[42] Cancer Research UK. Bowel cancer screening n.d. https://www.cancerresearchuk.org/about-cancer/bowel-cancer/getting-diagnosed/screening (accessed February 17, 2025)

[43] American Cancer Society. Testing for Colorectal Cancer | How Is Colorectal Cancer Diagnosed? n.d. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/how-diagnosed.html (accessed February 17, 2025)

[44] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology—Colorectal Cancer Screening—Version 1. 2024. NCCN n.d. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429 (accessed February 17, 2025)

[45] Centers for Medicare & Medicaid Services. MLN Matters: MM13017; Related CR 13017 - Removal of a National Coverage Determination & Expansion of Coverage of Colorectal Cancer Screening 2023. https://www.cms.gov/files/document/mm13017-removal-national-coverage-determination-expansion-coverage-colorectal-cancer-screening.pdf (accessed February 17, 2024)

[46] Centers for Medicare & Medicaid Services. NCD—Colorectal Cancer Screening Tests (2103) n.d. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=281 (accessed February 17, 2025)

[47] Press Release. FDA Approves ColoSenseTM—Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test—Geneoscopy—Transforming Gastrointestinal Health 2024. https://www.geneoscopy.com/fda-approves-colosense-geneoscopys-noninvasive-multi-target-stool-rna-mtrna-colorectal-cancer-screening-test/ (accessed February 17, 2025)

[48] Press Release. FDA Approves Exact Sciences’ Cologuard Plus Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening. Exact Sciences 2024. https://www.exactsciences.com/newsroom/press-releases/fda-approves-exact-sciences-cologuard-plus-test (accessed March 4, 2025)

[49] Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. New England Journal of Medicine. 2014; 370: 1287-1297.

[50] Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget Stool RNA Test for Colorectal Cancer Screening. JAMA. 2023; 330: 1760-1768.

[51] Potter NT, Hurban P, White MN, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014; 60: 1183-1191.

[52] Chung DC, Gray DM, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. New England Journal of Medicine. 2024; 390: 973-983.

[53] Kankanala VL, Mukkamalla SKR. Carcinoembryonic Antigen. StatPearls Publishing; 2024

[54] Fisher DA, Princic N, Miller-Wilson L-A, et al. Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer. Int J Colorectal Dis. 2022; 37: 719-721.

[55] Raymond V, Foster G, Hong Y, et al. S295 Implementation of Blood-Based Colorectal Cancer Screening: real-world clinical experience. Official Journal of the American College of Gastroenterology | ACG. 2023; 118: S218.

[56] Connal S, Cameron JM, Sala A, et al. Liquid biopsies: the future of cancer early detection. Journal of Translational Medicine. 2023; 21: 118.

[57] Chun J, Kim J-H, Youn YH, Park H. Noninvasive testing for colorectal cancer screening: where are we now?. Korean Society of Gastrointestinal Cancer. 2023; 11: 85-92.

[58] Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening. Clinical Gastroenterology and Hepatology. 2023; 21: 604-616.

[59] Press Release. Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer. Freenome 2024. https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/ (accessed February 17, 2025)

[60] Shaukat A, Burke CA, Chan AT, et al. Clinical validation of a circulating tumor DNA–based blood test to screen for colorectal cancer. JAMA. 2025; 334: 56-63.

[61] Han YD, Oh TJ, Chung T-H, et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clinical Epigenetics. 2019; 11: 51.

[62] Ciarloni L, Ehrensberger SH, Imaizumi N, et al. Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer. Clinical Cancer Research. 2016; 22: 4604-4611.

[63] Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021; 1875: 188464.

[64] Takakura D, Ohashi S, Kobayashi N, Tokuhisa M, Ichikawa Y, Kawasaki N. Targeted O-glycoproteomics for the development of diagnostic markers for advanced colorectal cancer. Front Oncol. 2023; 13.

[65] Viode A, van Zalm P, Smolen KK, et al. A simple, time- and cost-effective, high-throughput depletion strategy for deep plasma proteomics. Science Advances. 2023; 9: eadf9717.

[66] Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023; 622: 348-358.

[67] Bhardwaj M, Gies A, Weigl K, et al. Evaluation and Validation of plasma proteins using two different protein detection methods for early detection of colorectal cancer. Cancers. 2019; 11: 1426.

[68] Qian J, Tikk K, Werner S, et al. Biomarker discovery study of inflammatory proteins for colorectal cancer early detection demonstrated importance of screening setting validation. Journal of Clinical Epidemiology. 2018; 104: 24-34.

[69] Xu Y, Ritchie SC, Liang Y, et al. An atlas of genetic scores to predict multi-omic traits. Nature. 2023; 616: 123-131.

[70] Li H, Vanarsa K, Zhang T, et al. Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer. J Gastroenterol. 2021; 56: 659-672.

[71] Suhre K, Venkataraman GR, Guturu H, et al. Nanoparticle enrichment mass-spectrometry proteomics identifies protein-altering variants for precise pQTL mapping. Nat Commun. 2024; 15: 989.

[72] Press Release. Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults | Seer, Inc. n.d. https://investor.seer.bio/news-releases/news-release-details/seers-proteograph-platform-enables-unprecedented-20000-sample (accessed July 7, 2025)

[73] Sun J, Zhao J, Jiang F, et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Medicine. 2023; 15: 75.

[74] Sun X, Shu X-O, Lan Q, et al. Prospective proteomic study identifies potential circulating protein biomarkers for colorectal cancer risk. Cancers (Basel). 2022; 14: 3261.

[75] Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023; 622: 329-338.

[76] Liu C-Y, Huang T-T, Chen J-L, et al. Significance of kynurenine 3-monooxygenase expression in colorectal cancer. Front Oncol. 2021; 11: 620361.

[77] Cui W, Guo M, Liu D, et al. Gut microbial metabolite facilitates colorectal cancer development via ferroptosis inhibition. Nat Cell Biol. 2024; 26: 124-137.

[78] Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host & Microbe. 2022; 30: 289-300.

[79] Bel'skaya LV. Use of IR spectroscopy in cancer diagnosis. A review. J Appl Spectrosc. 2019; 86: 187-205.

[80] Paraskevaidi M, Matthew BJ, Holly BJ, et al. Clinical applications of infrared and Raman spectroscopy in the fields of cancer and infectious diseases. Applied Spectroscopy Reviews. 2021; 56: 804-868.

[81] Sala A, Anderson DJ, Brennan PM, et al. Biofluid diagnostics by FTIR spectroscopy: a platform technology for cancer detection. Cancer Letters. 2020; 477: 122-130.

[82] Dxcover. Dxcover PANAROMIC Platform For Earlier Detection of Cancer 2024. https://www.dxcover.com/panaromic/ (accessed February 17, 2025)

[83] Cameron JM, Rinaldi C, Butler HJ, et al. Stratifying brain tumour histological sub-types: the application of ATR-FTIR serum spectroscopy in secondary care. Cancers (Basel).. 2020; 12: 1710.

[84] Sala A, Cameron JM, Jenkins CA, et al. Liquid biopsy for pancreatic cancer detection using infrared spectroscopy. Cancers. 2022; 14: 3048.

[85] Cameron JM, Sala A, Antoniou G, et al. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types. Br J Cancer. 2023; 129: 1658-1666.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.